Loading
Talquetamab, an antibody that pulls T cells onto a new myeloma target called GPRC5D, produced responses in about seven in ten heavily pretreated patients, including those already treated with BCMA-directed therapy.
Phase 1 dose-escalation and expansion study of 288 patients with relapsed or refractory multiple myeloma treated with subcutaneous talquetamab at 405 micrograms per kilogram weekly or 800 micrograms per kilogram every two weeks.
Response rates were about 70 percent at both doses with a median duration of response of about 10 months; cytokine release syndrome was common but mostly low grade, and skin, nail and taste changes were characteristic.
A second bispecific target beyond BCMA gives patients an option after BCMA-directed CAR-T or bispecifics have failed; it was approved in 2023.
Shares MonumenTAL-1, Talquetamab, Relapsed or refractory multiple myeloma.
Shares Talquetamab, Relapsed or refractory multiple myeloma.
Shares Talquetamab, Relapsed or refractory multiple myeloma.
Shares Talquetamab, Relapsed or refractory multiple myeloma.
Shares Talquetamab, Relapsed or refractory multiple myeloma, New England Journal of Medicine.
Shares Talquetamab, Relapsed or refractory multiple myeloma.
Shares Relapsed or refractory multiple myeloma, New England Journal of Medicine.
Shares Relapsed or refractory multiple myeloma, New England Journal of Medicine.